APPROACHES TO THE FUTURE ENGINEERS FOREIGN COMMUNICATIVE CULTURE FORMATION

Purpose: The main aim of the article is to define the approaches to the formation of future engineers’ communicative culture. The main research method used while working on the article is analysis of the domestic and foreign publication space for critical consideration of different ideas on the pedagogical problem of the future engineers’ foreign language communicative culture formation process. Methodology: In this study Content abstraction, generalization and the comparative method was applied. Result: The approaches (cultural, connectivism, technological, axiological, communicative, environmental approach) will help to the formation of the communicative culture of future engineers in the process of foreign language training. Applications: This research can be used for engineers and companies. Novelty/Originality: In this research, the model of approaches to future engineers' foreign communicative culture formation is presented in a comprehensive and complete manner

Применение различных схем противовирусной терапии ОРВИ у детей

To optimize selection of antiviral agents for children in routine practice of ARVI management, a double-center, prospective, open-label, randomized study of efficacy and tolerability of schemes including Ergoferon, Cagocel, Arbidol in children > 3 years was performed throughout two epidemic seasons (fall 2012 — spring 2014). In total 152 children with ARVI symptoms lasting for no more than 48 hours were randomized into 3 groups, i.e. Ergoferon (group E, n = 67), Cagocel (group C, n = 40), Arbidol (group A, n = 45). At visits 2 and 3 proportion of children with normalized body temperature (primary criterion) and intensity of intoxication and catarrhal syndrome were evaluated. At visit 3 the following parameters were measured: efficacy index (efficacy and tolerability assessment by the doctor using CGI scale) and evaluation of safety and tolerability of the study drug by parents/representatives of the child; incidence of medical product prescriptions was recorded, i.e. the total number of prescriptions per group, incidence and duration of administration of individual groups of agents. To analyze and evaluate the data obtained, conventional methods of parametric and non-parametric statistics were applied. Groups C and A were not statistically different in baseline characteristics and throughout efficacy criteria assessment. A new group 2 (n=85) was generated out of these groups for further analysis. At visit 2 group 1 and group 2 showed normalization in morning and evening body temperature in 76% and 79% in group 1, respectively, vs. 73% and 79% — in group 2 (2, p > 0.05). 100% subjects in group 1 and 98% — in group 2 did not have intoxication signs, or the rank value of mild intoxication did not exceed 1 (mild). Proportion of subjects with mild catarrhal syndrome at rank 2—3 in group 1 vs. baseline reduced from 15% to 3%, in group 2 — from 18% to 8%. At visit 3, 94% subjects in group 1 and 95% — in group did not show clinical intoxication signs. Almost every one in three children in both groups had catarrhal signs completely resolved by the end of the treatment, in 70% and 65% cases in groups 1 and 2 severity of catarrhal syndrome did not exceed rank 1 (2, p > 0.05). No adverse effects associated with the study scheme components have been reported during the study. Efficacy and tolerability evaluation by the doctors using CGI in group 1 was 3.37 ± 0.65 (M ± SD, 95% CI 3.22-3.53) vs. 3.23 ± 0.77 (M ± SD, 95%CI 3.08—3.39) in group 2 (Т-test, p = 0.38). In group 1 maximum rating (4 scores) was assigned by the doctors in 46%, minimum one (2 scores) — in 9%, while in group 2 the equivalent proportions were 40% and 16%, respectively (p = 0.44 for maximum score and p = 0.17 for minimum score). Therapeutic efficacy evaluation by  parents in group 1 was 3.73 ± 0.57 (M ± SD, 95% CI 3.59-3.87) vs. 3.35 ± 0.72 (M ± SD, 95%CI 3.20—3.50) in group 2; Т-test, p = 0.04. According to frequency assessment, positive scoring (4-5 scores) was more prevalent among parents in group 1: 71% vs. 44% (group 2), 2 test, p = 0.001, minimum scoring (2 scores) was less common in group 1: 1.5% vs. 12% (group 2),?2 test, p = 0.02. Evaluation of therapeutic tolerability by parents in group 1 (4.04 ± 0.53, 95%CI 3.91—4.18) was higher as compared to group 2 (3.82 ± 0.53, 95%CI 3.71—3.93); Т-test, p = 0.01. Maximum scoring (5 scores) was obtained in group 1 in 16% cases, in group 2 — 6% (2 test, p = 0.03). Analysis of additional drug prescriptions revealed that 3.6 ± 1.2 prescriptions have been made on average in group 1 vs. 5.0 ± 1.2 in group 2 (Т-test, р = 0.01). Proportion of children receiving more than 5 drugs was 18% in group 1 vs. 32% in group 2 (2 test, p = 0.05). Seven drugs were given to 3% children in group 1 and 12% — in group 2 (exact Fisher’s test, p = 0.067). Duration of therapy with H1-histamine blockers in group 1 was 5 days (Me: 5.0 (5.0; 6.0) vs. 8.5 days (Me: 8.5 (7.5; 10.0) in group 2 (U-test, р = 0.006). Therefore, comparable clinical efficacy and tolerability of anti-ARVI therapeutic schemes were revealed in children using Ergoferon, Cagocel and Arbidol. At that Ergoferon group showed higher therapeutic quality scoring (efficacy and tolerability), both according to the doctors (CGI scale) and parents. Reduced number of prescriptions and duration of drug therapy in Ergoferon group for ARVI management were revealed.С целью оптимизации выбора противовирусных средств у детей в рутинной практике лечения ОРВИ было проведено двухцентровое проспективное открытое рандомизированное исследование эффективности и переносимости схем терапии с применением Эргоферона, Кагоцела, Арбидола у детей в возрасте старше 3 лет на протяжении двух эпидсезонов (осень 2012 — весна 2014 гг.). 152 ребенка с симптомами ОРВИ, продолжительностью не более 48 часов, были рандомизированы в 3 группы, в которых для лечения ОРВИ применялись Эргоферон (группа Э, 67 пациентов), Кагоцел (группа К, 40 пациентов), Арбидол (группа А, 45 пациентов). На 2-м и 3-м визитах оценивалась доля пациентов с нормализацией температуры тела (первичный критерий), выраженность интоксикационного и катарального синдромов. На 3-м визите регистрировались: индекс эффективности (оценка врачом эффективности и переносимости терапии по шкале CGI) и оценки эффективности и переносимости исследуемого препарата со слов родителей/представителей ребенка; анализировалась частота назначения медикаментов — общее число назначений в группе, частота и продолжительность применения отдельных групп препаратов. Для анализа и оценки полученных данных применялись стандартные методы параметрической и непараметрической статистики. Группы К и А не имели статистически значимых различий в исходных характеристиках и в динамике оцениваемых критериев эффективности и для дальнейшего анализа из них была сформирована новая группа 2 (85 пациентов). На 2-м визите отмечалась нормализация утренней и вечерней температуры тела в 76 и 79% соответственно, в 1-й группе, против 73 и 79% — во 2-й группе (2, p > 0,05). 100% пациентов из 1-й группы и 98% пациентов — из 2-й группы не имели признаков интоксикации или ранговый показатель синдрома интоксикации был не выше 1 (слабо выражен). Доля пациентов с выраженностью катарального синдрома на уровне 2-3 рангов в 1-й группе по сравнению с исходными данными сократилась с 15 до 3%, во 2-й группе — с 18 до 8%. На 3-м визите 94% пациентов в 1-й группе и 95% во — 2-й группе не имели клинических проявлений интоксикации, практически, каждый третий ребенок из обеих групп полностью избавился от катаральных явлений к окончанию лечения, в 70 и в 65% случаев в 1-й и 2-й группах выраженность катарального синдрома не превышала 1 ранга (2, p > 0,05). В ходе проведения исследования не было зарегистрировано побочных эффектов, связанных с приемом тех или иных компонентов исследуемых схем терапии. Оценка эффективности и переносимости, данная врачами по шкале CGI в 1-й группе составила 3,37 ± 0,65 (M ± SD, 95%CI 3,22—3,53), против 3,23 ± 0,77 (M ± SD, 95%CI 3,08-3,39) во 2-й группе (Т-критерий, p = 0,38). В 1-й группе максимальную оценку (4 балла) врачи поставили в 46%, а минимальную (2 балла) — в 9%, в то время, как во 2-й группе аналогичные доли составили 40 и 16% соответственно (p = 0,44 для максимальной оценки и p = 0,17 для минимальной оценки). Оценка эффективности терапии родителями в 1-й группе составила 3,73 ± 0,57 (M ± SD, 95%CI 3,59-3,87) против 3,35 ± ± 0,72 (M ± SD, 95%CI 3,20—3,50) в 2-й группе; Т-критерий, p = 0,04. По данным частотного анализа балльных оценок, положительные оценки (4—5 баллов) чаще ставили родители детей из 1-й группы: 71% против 44% (2-я группа), критерий 2, p = = 0,001, минимальные оценки (2 балла) реже встречались во 1-й группе: 1,5% против 12% (2-я группа), критерий 2, p = 0,02. Оценка переносимости терапии, данная родителями в 1-й группе (4,04 ± 0,53, 95%CI 3,91-4,18) была более высокой, чем в 2-й группе (3,82 ± 0,53, 95%CI 3,71—3,93); Т-критерий, p = 0,01. Максимальная оценка в 5 баллов получена в 1-й группе в 16% случаев, а в 2-й группе — 6% (критерий 2, p = 0,03). В ходе анализа дополнительных медикаментозных назначений было выявлено, что в среднем в 1-й группе осуществлялось 3,6 ± ± 1,2 назначений, против 5,0 ± 1,2 во 2-й группе (Т-критерий, р = 0,01). Доля детей, получавших более 5 медикаментов, в 1-й группе составила 18%, тогда как во 2-й группе доля таких назначений была выше — 32% (критерий 2, p = 0,05). 7 препаратов получало 3% детей в 1-й группе и 12% пациентов во 2-й группе (точный критерий Фишера, p = 0,067). Продолжительности терапии H1 гистамино-блокаторами 1-й группе составила 5 дней (Me: 5,0 (5,0; 6,0) против 8,5 дней (Me: 8,5 (7,5; 10,0) их использования во 2-й группе (U-критерий, р = 0,006). Таким образом, выявлена сопоставимая клиническая эффективность и переносимость применения схем терапии ОРВИ у детей с использованием Эргоферона, Кагоцела и Арбидола. При этом в группе детей, получавших Эргоферон, чаще регистрировались более высокие оценки качества терапии (эффективность и переносимость), как со стороны врачей (по шкале CGI), так и со стороны родителей. Выявлено уменьшение числа назначаемых препаратов и снижение продолжительности применения препаратов в группе детей, получавших Эргоферон для лечения ОРВИ

Опыт применения фокусированного ультразвукового исследования сердца у пациентов с COVID-19 в Prone-позиции

Aim of the study. To study the experience of using focused transthoracic echocardiography in patients with COVID-19 in prone position (fEchoPr) in intensive care units (ICU).Materials and methods. The retrospective observational study included 53 patients (period from 15 April to 31 December 2020). Inclusion criteria: confirmed diagnosis of COVID-19, availability of fEchoPr data, outcome certainty (discharge/death). We analyzed electronic medical records. The fEchoPr was performed in patients in the prone position with a bolster under the left side of the chest and left arm raised (‘swimmer’s position’). We assessed the systolic function of the right ventricle (RV) (tricuspid annular plane systolic excursion (TAPSE)), RV size, RV/LV ratio, systolic function of the left ventricle (LV) (left ventricular outflow tract velocity time integral. (LVOT VTI)), and pulmonary hypertension (PH) (tricuspid regurgitation peak gradient (PGTR). Depending on the results, the patients were divided into 2 groups: informative (+fEchoPr) and non-informative (–fEchoPr) examinations.Results. There was no statistically significant difference in the groups (+fEcho n = 35 vs –fEcho n = 18) by age (65.6 ± 15.3 vs 60.2 ± 15.8, p > 0.05), by gender (male: 23 (65.7%) vs 14 (77.8%), p > 0.05), by body mass index (31.3 ± 5.3 kg/m 2 vs 29.5 ± 5.4 kg/m2 , p > 0.05), by mechanical ventilation support (24 (68.6%) vs 17 (94.4%), p = 0.074), by NEWS scale indicators (6.9 ± 3.7 vs 8.5 ± 3.5 points), by mortality (82.8% vs 94.4%, p > 0.05). Correlation analysis revealed a moderate inverse relationship between being on mechanical ventilation and the informative value of the study (Spearman's r = −0.30 at p = 0.033). In the +fEchoPr group, the correct measurement of TAPSE and RV/LV was carried out in 100%: a decrease in RV systolic function was recorded in 5 patients (14%), expansion of the RV in 13 patients (37%). Signs of PH were detected in 11 patients (31%), PGTR could not be measured in 10 patients (28%). LV systolic dysfunction was detected in 7 patients (20%). No pathology was detected in 16 patients (46%). One patient was diagnosed with infective endocarditis of native mitral valve, which was later confirmed by autopsy.Conclusion. In 66% of cases, fEchoPr examinations were informative, especially in terms of assessing the state of the right heart. fEchoPr examination is an affordable, valid and reproducible method to assess and monitor the state of the heart in ICU patients.Цель исследования: изучение опыта применения фокусированного трансторакального эхокардиографического исследования в Prone-позиции (фЭхоPr) в отделениях реанимации и интенсивной терапии (ОРИТ) у пациентов с COVID-19.Материал и методы. В ретроспективное наблюдательное исследование включено 53 пациента (период 15.04–31.12.20). Критерии включения: подтвержденный диагноз COVID-19, наличие данных фЭхоPr, определенность исхода (выписка/смерть). Анализировались электронные истории болезни. фЭхоPr выполнялось в положении пациента на животе с валиком под левой частью грудной клетки и поднятой левой рукой (“поза пловца”). Проводилась оценка систолической функции правого желудочка (ПЖ) (измерение экскурсии фиброзного кольца трикуспидального клапана (TAPSE)), размера ПЖ, систолической функции левого желудочка (ЛЖ) (измерение интеграла линейной скорости кровотока в выходном тракте ЛЖ (VTIвтлж)), параметра ПЖ/ЛЖ, легочной гипертензии (ЛГ) (измерение пикового градиента трикуспидальной регургитации (PGTR)). В зависимости от результатов пациенты были разделены на 2 группы: информативные (+фЭхоPr) и неинформативные (−фЭхоPr) исследования.Результаты. Не выявлено статистически значимой разницы в группах (+фЭхоPr n = 35 vs -фЭхоPr n = 18) по возрасту (65,6 ± 15,3 года vs 60,2 ± 15,8 года, р > 0,05), полу (муж.: 23 (65,7%) vs 14 (77,8%), р > 0,05), индексу массы тела (31,3 ± 5,3 кг/м 2 vs 29,5 ± 5,4 кг/м2 , р > 0,05), нахождению на искусственной вентиляции легких (ИВЛ) (24 (68,6%) vs 17 (94,4%), р = 0,074), показателям шкалы NEWS (6,9 ± 3,7 vs 8,5 ± 3,5 балла), летальности (82,8% vs 94,4%, р > 0,05). Корреляционный анализ выявил умеренную обратную связь между нахождением на ИВЛ и информативностью исследования (r-Спирмена = −0,30 при р = 0,033). В группе +фЭхоPr корректное измерение TAPSE и ПЖ/ЛЖ проведено в 100%: снижение систолической функции ПЖ зафиксировано у 5 (14%), расширение ПЖ у 13 (37%) пациентов. Признаки ЛГ выявлены у 11 (31%), измерить PGTR не удалось у 10 (28%) человек. Систолическая дисфункция ЛЖ выявлена у 7 (20%). Не было выявлено патологии у 16 (46%) пациентов. У одного пациента диагностирован инфекционный эндокардит нативного митрального клапана, подтвердившийся при проведении аутопсии.Заключение. В 66% случаев проведение фЭхоPr было информативным, особенно в части оценки состояния правых отделов сердца. фЭхоPr – доступный, валидный и воспроизводимый метод оценки и мониторинга состояния сердца у пациентов в ОРИТ

The recombinant fusion protein CFP10–ESAT6–dIFN has protective effect against tuberculosis in guinea pigs

Development of effective vaccine candidates against tuberculosis (TB) is currently the most important challenge in the prevention of this disease since the BCG vaccine fails to guarantee a lifelong protection, while any other approved vaccine with better efficiency is still absent. The protective effect of the recombinant fusion protein CFP10–ESAT6–dIFN produced in a prokaryotic expression system (Escherichia coli) has been assessed in a guinea pig model of acute TB. The tested antigen comprises the Mycobacterium tuberculosis (Mtb) proteins ESAT6 and CFP10 as well as modified human γ-interferon (dIFN) for boosting the immune response. Double intradermal immunization of guinea pigs with the tested fusion protein (2 × 0.5 µg) induces a protective effect against subsequent Mtb infection. The immunized guinea pigs do not develop the symptoms of acute TB and their body weight gain was five times more as compared with the non-immunized infected guinea pigs. The animal group immunized with this dose of antigen displays the minimum morphological changes in the internal organs and insignificant inflammatory lesions in the liver tissue, which complies with a decrease in the bacterial load in the spleen and average Mtb counts in macrophages

Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation

<p>Abstract</p> <p>Background</p> <p>Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant neuromuscular disorder associated with the partial deletion of integral numbers of 3.3 kb D4Z4 DNA repeats within the subtelomere of chromosome 4q. A number of candidate FSHD genes, adenine nucleotide translocator 1 gene (<it>ANT1</it>), FSHD-related gene 1 (<it>FRG1</it>), <it>FRG2 </it>and <it>DUX4c</it>, upstream of the D4Z4 array (FSHD locus), and double homeobox chromosome 4 (<it>DUX4</it>) within the repeat itself, are upregulated in some patients, thus suggesting an underlying perturbation of the chromatin structure. Furthermore, a mouse model overexpressing <it>FRG1 </it>has been generated, displaying skeletal muscle defects.</p> <p>Results</p> <p>In the context of myogenic differentiation, we compared the chromatin structure and tridimensional interaction of the D4Z4 array and <it>FRG1 </it>gene promoter, and <it>FRG1 </it>expression, in control and FSHD cells. The <it>FRG1 </it>gene was prematurely expressed during FSHD myoblast differentiation, thus suggesting that the number of D4Z4 repeats in the array may affect the correct timing of <it>FRG1 </it>expression. Using chromosome conformation capture (3C) technology, we revealed that the <it>FRG1 </it>promoter and D4Z4 array physically interacted. Furthermore, this chromatin structure underwent dynamic changes during myogenic differentiation that led to the loosening of the <it>FRG1</it>/4q-D4Z4 array loop in myotubes. The <it>FRG1 </it>promoter in both normal and FSHD myoblasts was characterized by H3K27 trimethylation and Polycomb repressor complex binding, but these repression signs were replaced by H3K4 trimethylation during differentiation. The D4Z4 sequences behaved similarly, with H3K27 trimethylation and Polycomb binding being lost upon myogenic differentiation.</p> <p>Conclusion</p> <p>We propose a model in which the D4Z4 array may play a critical chromatin function as an orchestrator of <it>in cis </it>chromatin loops, thus suggesting that this repeat may play a role in coordinating gene expression.</p

DUX4c Is Up-Regulated in FSHD. It Induces the MYF5 Protein and Human Myoblast Proliferation

Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contractions of the D4Z4 repeat array in 4q35. We have previously identified a double homeobox gene (DUX4) within each D4Z4 unit that encodes a transcription factor expressed in FSHD but not control myoblasts. DUX4 and its target genes contribute to the global dysregulation of gene expression observed in FSHD. We have now characterized the homologous DUX4c gene mapped 42 kb centromeric of the D4Z4 repeat array. It encodes a 47-kDa protein with a double homeodomain identical to DUX4 but divergent in the carboxyl-terminal region. DUX4c was detected in primary myoblast extracts by Western blot with a specific antiserum, and was induced upon differentiation. The protein was increased about 2-fold in FSHD versus control myotubes but reached 2-10-fold induction in FSHD muscle biopsies. We have shown by Western blot and by a DNA-binding assay that DUX4c over-expression induced the MYF5 myogenic regulator and its DNA-binding activity. DUX4c might stabilize the MYF5 protein as we detected their interaction by co-immunoprecipitation. In keeping with the known role of Myf5 in myoblast accumulation during mouse muscle regeneration DUX4c over-expression activated proliferation of human primary myoblasts and inhibited their differentiation. Altogether, these results suggested that DUX4c could be involved in muscle regeneration and that changes in its expression could contribute to the FSHD pathology

MECHANICAL PROPERTIES OF SERVOVITE FILMS FORMED IN DURING FRICTION AQUEOUS SOLUTIONS OF CARBOXYLIC ACIDS

Introduction. The effect of the organic component nature in the systematic series of monocarboxylic acids on the tribological characteristics of the brass-steel friction pair in aqueous solutions is described. Dependence of the mechanical-and-physical properties of the antifriction films formed during friction on the nature of the lubricating composition is investigated. The work objectives are to study the applicability of carboxylic acids as an antifriction lubricant component; to assess their effect on the mechanical properties of the servovite film formed under the brass – steel friction.Materials and Methods. Tribological studies of the brass-steel friction pair on the AE-5 end-type friction machine are carried out. Roughness parameters of the servovite  film were determined through the optical profilometry. The microgeometry and the object structure at the nanoscale were considered using atomic force microscopy. The mechanical characteristics of the antifriction film were investigated using the instrument nanoindentation.Research Results. Tribological characteristics of the brass-steel tribocoupling and mechanical-and-physical properties of the servovite film formed during friction in the “brass – aqueous solution of carboxylic acid – steel” system were studied. It is established that the friction factor reduces when increasing the hydrocarbon radical length. The dimensional effects are found in the mechanical and tribological properties of the servovite film formed on the surface of the friction interaction in the carboxylic acids.Discussion and Conclusions. The study results show that the friction interaction on the wearing surface in the aqueous solutions of carboxylic acids forms a nanostructured servovite film which drops the friction factor. Its mechanical, physical and tribological parameters depend on the composition of the model lubricating medium. It is determined that the local mechanical-and-physical properties depend on the method of producing the servovite layer, the load and the size of the deformation zone. The results obtained can be used in the development of lubricants

The use of Different Schemes of Antiviral Therapy of Acute Respiratory Viral Infection in Children

To optimize selection of antiviral agents for children in routine practice of ARVI management, a double-center, prospective, open-label, randomized study of efficacy and tolerability of schemes including Ergoferon, Cagocel, Arbidol in children &gt; 3 years was performed throughout two epidemic seasons (fall 2012 — spring 2014). In total 152 children with ARVI symptoms lasting for no more than 48 hours were randomized into 3 groups, i.e. Ergoferon (group E, n = 67), Cagocel (group C, n = 40), Arbidol (group A, n = 45). At visits 2 and 3 proportion of children with normalized body temperature (primary criterion) and intensity of intoxication and catarrhal syndrome were evaluated. At visit 3 the following parameters were measured: efficacy index (efficacy and tolerability assessment by the doctor using CGI scale) and evaluation of safety and tolerability of the study drug by parents/representatives of the child; incidence of medical product prescriptions was recorded, i.e. the total number of prescriptions per group, incidence and duration of administration of individual groups of agents. To analyze and evaluate the data obtained, conventional methods of parametric and non-parametric statistics were applied. Groups C and A were not statistically different in baseline characteristics and throughout efficacy criteria assessment. A new group 2 (n=85) was generated out of these groups for further analysis. At visit 2 group 1 and group 2 showed normalization in morning and evening body temperature in 76% and 79% in group 1, respectively, vs. 73% and 79% — in group 2 (2, p &gt; 0.05). 100% subjects in group 1 and 98% — in group 2 did not have intoxication signs, or the rank value of mild intoxication did not exceed 1 (mild). Proportion of subjects with mild catarrhal syndrome at rank 2—3 in group 1 vs. baseline reduced from 15% to 3%, in group 2 — from 18% to 8%. At visit 3, 94% subjects in group 1 and 95% — in group did not show clinical intoxication signs. Almost every one in three children in both groups had catarrhal signs completely resolved by the end of the treatment, in 70% and 65% cases in groups 1 and 2 severity of catarrhal syndrome did not exceed rank 1 (2, p &gt; 0.05). No adverse effects associated with the study scheme components have been reported during the study. Efficacy and tolerability evaluation by the doctors using CGI in group 1 was 3.37 ± 0.65 (M ± SD, 95% CI 3.22-3.53) vs. 3.23 ± 0.77 (M ± SD, 95%CI 3.08—3.39) in group 2 (Т-test, p = 0.38). In group 1 maximum rating (4 scores) was assigned by the doctors in 46%, minimum one (2 scores) — in 9%, while in group 2 the equivalent proportions were 40% and 16%, respectively (p = 0.44 for maximum score and p = 0.17 for minimum score). Therapeutic efficacy evaluation by  parents in group 1 was 3.73 ± 0.57 (M ± SD, 95% CI 3.59-3.87) vs. 3.35 ± 0.72 (M ± SD, 95%CI 3.20—3.50) in group 2; Т-test, p = 0.04. According to frequency assessment, positive scoring (4-5 scores) was more prevalent among parents in group 1: 71% vs. 44% (group 2), 2 test, p = 0.001, minimum scoring (2 scores) was less common in group 1: 1.5% vs. 12% (group 2),?2 test, p = 0.02. Evaluation of therapeutic tolerability by parents in group 1 (4.04 ± 0.53, 95%CI 3.91—4.18) was higher as compared to group 2 (3.82 ± 0.53, 95%CI 3.71—3.93); Т-test, p = 0.01. Maximum scoring (5 scores) was obtained in group 1 in 16% cases, in group 2 — 6% (2 test, p = 0.03). Analysis of additional drug prescriptions revealed that 3.6 ± 1.2 prescriptions have been made on average in group 1 vs. 5.0 ± 1.2 in group 2 (Т-test, р = 0.01). Proportion of children receiving more than 5 drugs was 18% in group 1 vs. 32% in group 2 (2 test, p = 0.05). Seven drugs were given to 3% children in group 1 and 12% — in group 2 (exact Fisher’s test, p = 0.067). Duration of therapy with H1-histamine blockers in group 1 was 5 days (Me: 5.0 (5.0; 6.0) vs. 8.5 days (Me: 8.5 (7.5; 10.0) in group 2 (U-test, р = 0.006). Therefore, comparable clinical efficacy and tolerability of anti-ARVI therapeutic schemes were revealed in children using Ergoferon, Cagocel and Arbidol. At that Ergoferon group showed higher therapeutic quality scoring (efficacy and tolerability), both according to the doctors (CGI scale) and parents. Reduced number of prescriptions and duration of drug therapy in Ergoferon group for ARVI management were revealed